A5061287043- Ocular Infections and Treatments
- Intraocular Surgery and Lenses
- Ocular Surface and Contact Lens
- Corneal surgery and disorders
- Glaucoma and retinal disorders
- Corneal Surgery and Treatments
- Ocular Diseases and Behçet’s Syndrome
- Antibiotics Pharmacokinetics and Efficacy
- Allergic Rhinitis and Sensitization
- Ophthalmology and Visual Impairment Studies
- Bacterial Identification and Susceptibility Testing
- Retinal Diseases and Treatments
- Retinal and Optic Conditions
- Antibiotic Resistance in Bacteria
- Antimicrobial Resistance in Staphylococcus
- Dermatology and Skin Diseases
- Bacterial biofilms and quorum sensing
- Urticaria and Related Conditions
- Herpesvirus Infections and Treatments
- Mast cells and histamine
- Advanced Drug Delivery Systems
- Acne and Rosacea Treatments and Effects
- Sinusitis and nasal conditions
- Satellite Image Processing and Photogrammetry
- Facial Rejuvenation and Surgery Techniques
Scripps Clinic
2014-2024
Scripps Health
2014-2024
University of California, Irvine
2017-2024
Virginia Eye Consultants
2023-2024
University of Pikeville
2023
Scripps Green Hospital
2022
Christian Health Association of Nigeria
2021
University of Pittsburgh
2006-2019
Scripps Clinic Medical Group
2016-2019
University of California, Los Angeles
2017
PurposeTo evaluate netarsudil 0.02% ophthalmic solution in patients with open-angle glaucoma (OAG) and ocular hypertension (OHT).DesignDouble-masked, randomized, multicenter, parallel-group, noninferiority clinical study.MethodsAfter a washout of all prestudy hypotensive medications, 756 eligible elevated IOP were randomized to receive once day (q.d.) (251); twice (b.i.d.) (254); or timolol 0.5% b.i.d. (251) for 12 months, as well noninterventional Corneal Observation Study (COS) manifesting...
To evaluate the effect of 4 weeks treatment with azithromycin ophthalmic solution 1% on eyelid bacterial load, tear cytokines, and signs symptoms blepharitis.Twenty-six subjects (mean age 64.2 years; 65% female; 100% white) moderate to severe blepharitis received in absence warm compresses or scrubs for 28 days (twice a day 1 2 once 3-28). Blepharitis were evaluated at baseline (day 1) compared end 29) follow-up visits (2 posttreatment). Tear collection margin cultures performed treatment....
Purpose: Brilacidin (BRI), a novel defensin mimetic, was evaluated as an ocular anti-infective. Methods: In vitro: Potency based on MIC90s compared for 50 Staphylococcus aureus (SA), epidermidis (SE), and 25 each of Streptococcus pneumonia (SP), viridans (SV), Moraxella (MS), Haemophilus influenzae (HI), Pseudomonas aeruginosa (PA), Serratia marcescens (SM). vivo: Using established methods, toxicity graded with Draize testing. For efficacy testing, both corneas 24 rabbits were infected...